BioRestorative Concludes Phase II BRTX-100 Trial Enrolment for cLDD

BioRestorative concludes Phase II BRTX-100 trial enrolment for cLDD

BioRestorative Therapies has concluded patient enrolment in its Phase II study evaluating the efficacy and safety of BRTX-100 for cLDD.The post BioRestorative concludes Phase II BRTX-100 trial enrolment for cLDD appeared first on Clinical Trials Arena.

BioRestorative completes landmark Phase 2 enrollment for BRTX-100 in cLDD; advances toward Phase 3 and BLA - BioTuesdays

BioRestorative Therapies (NASDAQ: BRTX) has announced the completion of patient enrollment in its Phase 2 clinical trial evaluating the safety and efficacy of BRTX-100 for the treatment of chronic lumbar disc disease (cLDD). BRTX-100 is BioRestorative’s lead clinical candidate — an autologous, hypoxically cultured mesenchymal stem cell therapy engineered for delivery into low-oxygen, low-nutrient disc environments. With 99 patients enrolled acro…